US2005175631A1PendingUtilityA1

Hiv vaccine and method of use

59
Priority: Jan 14, 2002Filed: Jan 14, 2003Published: Aug 11, 2005
Est. expiryJan 14, 2022(expired)· nominal 20-yr term from priority
Inventors:Michael VajdyIndresh SrivastavaSusan BarnettDerek O'Hagan
A61K 2039/543C12N 2740/16034A61K 2039/6037A61K 9/0031A61K 2039/55594A61K 9/0034A61K 39/21C07K 14/005A61K 2039/55544C12N 2740/16222A61P 37/04A61K 9/0043A61K 39/12A61K 2039/575A61K 39/00
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention is directed to pharmaceutical compositions comprising an HIV antigen and a mucosal adjuvant and methods for raising an immune response in a subject by administering these compositions. Preferably, the pharmaceutical compositions of the invention can be used to treat or prevent HIV infection.

Claims

exact text as granted — not AI-modified
1 . A composition suitable for mucosal delivery comprising an HIV envelope antigen and a detoxified mutant A subunit of  E. coli  heat labile toxin (LT) selected from one or more of the group consisting of LTK63 and LTR72.  
     
     
         2 . The composition of  claim 1 , wherein said heat labile toxin is LTK63.  
     
     
         3 . The composition of  claim 1 , wherein said heat labile toxin is LTR72.  
     
     
         4 . The composition of  claim 1 , wherein said toxin comprises a holotoxin of said  E. coli  heat labile toxin.  
     
     
         5 . The composition of  claim 1 , wherein said envelope protein is selected from the group consisting of gp120, gp160 and ogp140.  
     
     
         6 . The composition of  claim 1 , wherein said HIV envelope antigen is optimized for immunogenicity.  
     
     
         7 . The composition of  claim 1 , wherein said composition further comprises a second HIV antigen.  
     
     
         8 . The composition of  claim 7 , wherein said second HIV antigen is optimized for immunogenicity.  
     
     
         9 . The composition of  claim 7 , wherein said second HIV antigen is selected from one or more of the group consisting of HIV structural proteins, HIV regulatory proteins, and HIV accessory proteins.  
     
     
         10 . The composition of  claim 9 , wherein said HIV structural protein is selected from the group consisting of Gag, Pol and envelope.  
     
     
         11 . The composition of  claim 9 , wherein said HIV regulatory protein is selected from the group consisting of Tat and Rev.  
     
     
         12 . The composition of  claim 9 , wherein said HIV accessory protein is selected from the group consisting of Vpu, Vpr, Vif, and Nef.  
     
     
         13 . The composition of  claim 10 , wherein said second HIV antigen is gag.  
     
     
         14 . The composition of  claim 1 , wherein said composition is suitable for intranasal delivery.  
     
     
         15 . The composition of  claim 1 , wherein said composition is suitable for intra-vaginal delivery.  
     
     
         16 . The composition of  claim 1 , wherein said composition is suitable for intra-rectal delivery.  
     
     
         17 . A composition suitable for mucosal delivery comprising a polynucleotide encoding for an HIV envelope protein and a detoxified mutant A subunit of  E. coli  heat labile toxin (LT) selected from one or more of the group consisting of LTK63 and LTR72.  
     
     
         18 . A composition suitable for mucosal delivery comprising an HIV envelope protein and a polynucleotide encoding a detoxified mutant A subunit of  E. coli  heat labile toxin (LT) selected from one or more of the group consisting of LTK63 and LTR72.  
     
     
         19 . A method for raising an immune response in a subject comprising mucosally administering a composition comprising an HIV envelope antigen and a detoxified mutant A subunit of  E. coli  heat labile toxin (LT) selected from the group consisting of LTK63 and LTR72.  
     
     
         20 . The method of  claim 19 , wherein said heat labile toxin is LTK63.  
     
     
         21 . The method of  claim 19 , wherein said heat labile toxin is LTR72.  
     
     
         22 . The method of  claim 19 , wherein said toxin comprises a holotoxin of said  E. coli  heat labile toxin.  
     
     
         23 . The method of  claim 19 , wherein said envelope protein is selected from the group consisting of gp120, gp160 and ogp140.  
     
     
         24 . The method of  claim 19 , further comprising administering a second HIV antigen.  
     
     
         25 . The method of  claim 24 , wherein said second HIV antigen is selected from one or more of the group consisting of HIV structural proteins, HIV regulatory proteins, and HIV accessory proteins.  
     
     
         26 . The method of  claim 24 , wherein said second HIV antigen is gag.  
     
     
         27 . The method of  claim 17  wherein said composition is administered intranasally.  
     
     
         26 . The method of  claim 19 , wherein said composition is administered intravaginally.  
     
     
         27 . The method of  claim 19 , wherein said composition is administered intrarectally.  
     
     
         28 . A method for raising an immune response in a subject comprising mucosally administering a composition comprising a polynucleotide encoding an HIV envelope antigen and a detoxified mutant A subunit of  E. coli  heat labile toxin (LT) selected from the group consisting of LTK63 and LTR72.  
     
     
         29 . A method for raising an immune response in a subject comprising mucosally administering a composition comprising an HIV envelope antigen and a polynucleotide encoding a detoxified mutant A subunit of  E. coli  heat labile toxin (LT) selected from the group consisting of LTK63 and LTR72.

Join the waitlist — get patent alerts

Track US2005175631A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.